학술논문
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
Document Type
Article
Author
Yamamoto, Gaku; Asahina, Hajime; Honjo, Osamu; Sumi, Toshiyuki; Nakamura, Atsushi; Ito, Kenichiro; Kikuchi, Hajime; Hommura, Fumihiro; Honda, Ryoichi; Yokoo, Keiki; Fujita, Yuka; Oizumi, Satoshi; Morita, Ryo; Ikezawa, Yasuyuki; Tanaka, Hisashi; Kimura, Nozomu; Sasaki, Takaaki; Sukoh, Noriaki; Takashina, Taichi; Harada, Toshiyuki
Source
Subject
*EPIDERMAL growth factor receptors
*NON-small-cell lung carcinoma
*EPIDERMAL growth factor
*OLDER patients
*OSIMERTINIB
*OVERALL survival
*
*
*
*
*
Language
ISSN
2045-2322
Abstract
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1–73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9–23.9) months. The median overall survival was not reached (95% confidence interval 24.6–not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis. [ABSTRACT FROM AUTHOR]